Middle-class Americans sell plasma to manage rising costs

Plasma sellers, drawn primarily by financial incentives rather than altruism, experience both physical challenges and regulatory scrutiny at centers like B Positive in Pennsylvania. CEO Ben Ruder highlights the business’s tight margins and fluctuating payment rates based on demand. Sellers face health risks, including bruising and potential allergic reactions, while the FDA allows frequent donations yet lacks comprehensive studies on long-term effects. Individuals like Jill Chamberlain rely on plasma sales for essential expenses, navigating a demanding process that includes health screenings and frequent questioning.

Want More Context? 🔎